^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + ALK mutation

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956; 238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    11ms
    Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer. (PubMed, Oncol Lett)
    EGFR mutation leads to more extrapulmonary metastases. Median OS was superior in ALK-rearranged NSCLC than EGFR-mutated NSCLC regardless of brain metastases.
    Clinical data • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • EGFR mutation + ALK mutation
    12ms
    Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country. (PubMed, JCO Glob Oncol)
    This real-world data analysis demonstrated that targeted therapies improve the survival of patients with NSCLC with actionable mutations, which supports a recommendation for widening access to broad-based genomic testing and targeted therapies.
    Retrospective data • Review • Journal • Real-world evidence • Real-world
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    1year
    Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Sep 2024 --> Jan 2025
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR mutation + ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed
    1year
    Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer. (PubMed, Eur J Cancer)
    Similarly, more frequent surveillance imaging than what is considered standard-of-care may identify disease progression earlier than what is expected in real-world clinical practice and therefore embellish the magnitude of benefit between a targeted therapy and the control arm. While targeted therapies have provided clinical benefit for individuals with oncogenic driven NSCLC, physicians and patients must be cognizant that clinical trial deviations from standard-of-care imaging practices may have embellished the magnitude of benefit for several of these therapies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    over1year
    The Characteristics of Plasma Sample NGS Analysis in the Detection of Lung Cancer Driver Genes (IASLC-WCLC 2024)
    Only a few driver mutations were detected exclusively in plasma samples. Characteristics of detected driver genes by NGS analysis Tissue Plasma EGFR 63 37 ALK 11 2 ROS1 8 4 BRAF 5 3 MET 8 3 RET 4 3 KRAS-G12C 13 9 HER2 4 6
    PD(L)-1 Biomarker • IO biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • KRAS G12C • ALK mutation • KRAS G12 • EGFR mutation + ALK mutation
    |
    Oncomine Precision Assay
    almost2years
    STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations. (PubMed, Clin Lung Cancer)
    Enrollment in the STAR-121 study commenced on October 12, 2022, and is currently ongoing with completion planned by September 2024. The study completion is expected by December 2027.
    P3 data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression • EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab) • Yutuo (zimberelimab) • domvanalimab (AB154)
    almost2years
    Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC (clinicaltrials.gov)
    P2/3, N=230, Recruiting, Canadian Cancer Trials Group | Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=50 --> 230 | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab)
    2years
    Clinical Challenge of Two Competing Targetable Mutations in Non-Small-Cell Lung Cancer: A Case Report. (PubMed, Diagnostics (Basel))
    We herein present an interesting case following the course of progression of a patient with synchronous lung cancers with a discordant mutation profile. The importance of this modality in the follow-up of lung cancer patients is illustrated, and the therapeutic implications of coexisting oncogenic drivers are briefly discussed.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • ALK mutation • EGFR mutation + ALK mutation
    2years
    Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients. (PubMed, Cancers (Basel))
    Although the sample size of patients receiving targeted therapies was limited, the study highlighted improved overall survival and progression-free survival rates compared to earlier trials, suggesting advancements in systemic lung metastasis treatment. The study suggests that as more targeted therapies emerge, the prospects for increased overall survival and progression-free survival in lung brain metastasis patients will likely improve.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR amplification • ALK rearrangement • ALK mutation • ALK amplification • EGFR mutation + ALK mutation
    over2years
    Molecular heterogeneity of Primary liver carcinomas: early study (ECP 2023)
    HCC CK19+/CK7+ targeted therapy might benefit from a CTNNB1, TP53, ALK, EGFR, MAP2K2, RET, PTEN, and IDH2 panel, standardized for PLC spectrum. This knowledge would allow better understanding the clinical course and PLC heterogeneity, together with improving tumor classification and treatment.
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR4 (Fibroblast growth factor receptor 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • KRT19 (Keratin 19)
    |
    TP53 mutation • EGFR mutation • PIK3CA mutation • KIT mutation • ALK mutation • AR mutation • PDGFRA mutation • ERBB3 mutation • EGFR mutation + PIK3CA mutation • EGFR mutation + ALK mutation
    |
    Oncomine Precision Assay
    over2years
    Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma (IASLC-WCLC 2023)
    Filipino patients with lung adenocarcinoma albeit small in sample size, have remarkable diversity in molecular profile while confirming reported EGFR and ALK values. CTC values were generally low despite being at advanced stages. CD133, KRT19 and MUC1 expression were detected in half of the samples and may find diagnostic and therapeutic utility.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MUC1 (Mucin 1) • KRT19 (Keratin 19)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK mutation • EGFR G719X • EGFR exon 18 mutation • MUC1 expression • CD133 expression • EGFR mutation + ALK mutation
    over2years
    Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jun 2023 --> Jun 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR mutation + ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed